One study reported that among patients with advanced NSCLC receiving nivolumab treatment, treatment responders exhibited approximately two-fold higher baseline levels of PD1+CD8+ T cells in the peripheral blood than non-responders. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.